LGVN | Longeveron Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.0201 - 2.0400
52 Week Range	0.7710 - 23.90
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	21,827
Average Volume	1,233,492
Shares Outstanding	14,359,478
Market Cap	29,293,335
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.23
Forward P/E Ratio	N/A
EPS	-8.86
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	23
Country	USA
Website	LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

LGVN's peers: APVO, NTRB, ABVC, EDSA, IKT, INDP, QNRX, RNXT, VRAX, GBIO, KRON, ERAS, CCCC, EWTX, SRZN, BOLT, LRMR, KROS, KZR, BWV, REVB, HILS, KPRX, KTTA, BTTX, FBRX, NRSN, NRXP, VRPX, VYNE

*Chart delayed

Analyzing fundamentals for LGVN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see LGVN Fundamentals page.

Watching at LGVN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on LGVN Technicals page.